Valuation: Conavi Medical Corp.

Market Cap 2.21Cr 1.58Cr 1.37Cr 1.3Cr 1.18Cr 151.23Cr 2.22Cr 16Cr 6Cr 77Cr 5.92Cr 5.79Cr 247.4Cr P/E 2024 *
-
P/E 2025 -1.88x
Enterprise Value 3.61Cr 2.58Cr 2.25Cr 2.12Cr 1.93Cr 247.58Cr 3.63Cr 25Cr 9.82Cr 125.87Cr 9.69Cr 9.48Cr 405.01Cr EV / Sales 2024 *
-
EV / Sales 2025 7.18x
Free-Float
66.52%
Yield 2024 *
-
Yield 2025 -
1 day+0.90%
1 week-4.49%
Current month-4.88%
1 month-14.70%
3 months-31.97%
6 months-59.80%
Current year-65.23%
1 week 0.1
Extreme 0.104
0.12
1 month 0.1
Extreme 0.1007
0.16
Current year 0.1
Extreme 0.1007
0.43
1 year 0.1
Extreme 0.1007
0.56
3 years 0
Extreme 0.0007
1
5 years 0
Extreme 0.0007
1
10 years 0
Extreme 0.0007
1
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-4.49% - - 1.58Cr
-1.04%+6.83%+35.84%+28.05% 24TCr
-0.32%+5.83%+9.58%-17.01% 15TCr
+2.55%+6.55%-10.35%+31.26% 14TCr
-0.48%+0.84%-55.70%-18.27% 6.28TCr
+0.01%+4.61%+18.61%+20.87% 5.09TCr
-1.69%-1.20%-19.89%-15.39% 4.82TCr
+0.08%+6.49%+23.87%+39.32% 4.41TCr
-1.88%+3.25%+40.14%+53.16% 4.14TCr
-2.27%+16.07%+133.21%+70.51% 3.62TCr
Average -0.41%+6.42%+19.48%+21.39% 9.03TCr
Weighted average by Cap. -0.26%+6.14%+15.57%+17.51%

Financials

2024 2025
Net sales 21.61L 15.43L 13.45L 12.7L 11.53L 15Cr 21.7L 1.52Cr 58.71L 7.53Cr 57.95L 56.66L 24Cr 91.22L 65.12L 56.78L 53.62L 48.69L 62Cr 91.6L 6.42Cr 2.48Cr 32Cr 2.45Cr 2.39Cr 102.22Cr
Net income -4.36Cr -3.11Cr -2.71Cr -2.56Cr -2.33Cr -298.75Cr -4.38Cr -31Cr -12Cr -151.89Cr -12Cr -11Cr -488.72Cr -2.05Cr -1.46Cr -1.28Cr -1.21Cr -1.1Cr -140.53Cr -2.06Cr -14Cr -5.57Cr -71Cr -5.5Cr -5.38Cr -229.89Cr
Net Debt 8.27Cr 5.91Cr 5.15Cr 4.86Cr 4.42Cr 566.75Cr 8.31Cr 58Cr 22Cr 288.14Cr 22Cr 22Cr 927.14Cr 1.41Cr 1Cr 87.55L 82.67L 75.07L 96Cr 1.41Cr 9.9Cr 3.82Cr 49Cr 3.77Cr 3.69Cr 157.6Cr
Logo Conavi Medical Corp.
Conavi Medical Corp. is a Canada-based medical device company. The Company is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary interventions (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.
Employees
-
Date Price Change Volume
18/26/18 $0.1149 +0.90% 10,441
17/26/17 $0.1139 +9.52% 1,89,624
16/26/16 $0.1040 -8.85% 63,413
15/26/15 $0.1141 -5.15% 1,12,031
11/26/11 $0.1203 +3.71% 7,281

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!